

EXHIBIT

5

Burlington Drug Company



Distribution excellence since 1891

June 11, 2014

The Honorable Faith S. Hochberg
United States District Court Judge
U.S.D.C., District of New Jersey
50 Walnut Street
Newark, NJ 07101

Re: In Re Neurontin Antitrust Litigation
No. MDL Docket No. 1479, Master File No. 02-1390 (FSH)

Dear Judge Hochberg:

I am writing in my capacity as Compliance/Regulatory Officer of Burlington Drug Company, Inc., a pharmaceutical wholesaler based in Milton, Vermont in support of the motion seeking final approval of the proposed settlement and fee award in the above-captioned litigation.

Burlington Drug is an absent class member in the above-described case, and I understand that Burlington Drug will have a claim to recovery out of the Settlement Fund in this case. Class Counsel has fully informed Burlington Drug of the facts and circumstances of the case, including the legal hurdles and other risks involved. Burlington Drug is satisfied that the proposed \$190 million case settlement is fair and adequate and that the proposed attorneys' fee award of one-third of the settlement amount is appropriate in this complex case. In addition to the value of the \$190 million settlement achieved on behalf of the class, Burlington Drug believes that this award is justified by the time and expense that class counsel put into prosecuting and favorably resolving this complex litigation.

For these reasons, Burlington Drug asks the Court to approve the settlement and supports class counsel's application for attorneys' fees and reimbursement of costs.

Very truly yours,

Margaret M. Glazier